Apnimed to Participate in the 2023 BIO International Convention
May 23, 2023 07:00 ET
|
Apnimed, Inc.
CAMBRIDGE, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea...
Apnimed Presented Positive Phase 2b Results on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea, for the First Time at ATS 2023
May 21, 2023 10:00 ET
|
Apnimed, Inc.
-- New MARIPOSA Study Data Showed AD109 Statistically Significantly Improved Both Objective and Subjective Outcomes in OSA Patients -- MARIPOSA Results Support Advancing AD109 to Phase 3 CAMBRIDGE,...
RespireRx Pharmaceuticals Inc. Announces Entry into Letter of Intent with Australian Headquartered CRO for Dronabinol Development for Obstructive Sleep Apnea
November 17, 2022 08:45 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Nov. 17, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
North America Sleep Tech Devices Market size to exceed $17 Bn by 2027, says Graphical Research
September 13, 2022 08:00 ET
|
Graphical Research
Pune, India, Sept. 13, 2022 (GLOBE NEWSWIRE) -- As per a recent industry report put forward by Graphical Research, the North America sleep tech devices market is forecast to register its name in...
Sleep Tech Devices Market to cross USD 67 billion by 2030, says Global Market Insights Inc.
May 25, 2022 03:17 ET
|
Global Market Insights Inc.
Selbyville, Delaware, May 25, 2022 (GLOBE NEWSWIRE) -- The sleep tech devices market value is expected to reach USD 67 billion by 2030, according to a new research report by Global Market Insights...
Sleep Tech Devices Market Trends 2021 | North America, Europe, & APAC Industry Forecasts 2027: Graphical Research
May 10, 2021 06:00 ET
|
Graphical Research
Pune, India, May 10, 2021 (GLOBE NEWSWIRE) -- The global sleep tech devices market size is predicted to show tremendous growth during the forecast period owing to the growing need among...
Vivos Therapeutics to Participate at the Q1 Virtual Investor Summit
March 11, 2021 07:55 ET
|
Vivos Therapeutics Inc.
Vivos management to present at 1:30 pm Eastern Time on March 23, 2021 HIGHLANDS RANCH, Colo., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Vivos Therapeutics, Inc. (“the Company”)...
Corrected Headline: RespireRx Pharmaceuticals Up Listed to OTCQB and Ticker Returns to RSPI
February 08, 2021 21:30 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Feb. 08, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company” or “we”), has been up listed from the OTC Pink Market and returns to the...
First Patient Implanted in the DREAM US Pivotal IDE Study, with the Genio® System for the Treatment of Obstructive Sleep Apnea (OSA)
November 17, 2020 01:00 ET
|
Nyxoah
First Patient Implanted in the DREAM US Pivotal IDE Study, with the Genio® System for the Treatment of Obstructive Sleep Apnea (OSA) DREAM is a pivotal, Investigational Device Exemption (IDE) study,...
InvestorBrandNetwork (IBN) Coverage Initiated for Vivos Therapeutics Inc.
June 11, 2020 08:30 ET
|
Vivos Therapeutics Inc.
NEW YORK, June 11, 2020 (GLOBE NEWSWIRE) -- via NetworkWire – Vivos Therapeutics Inc., a company focused on addressing the root causes of mild to moderate sleep apnea, today announces it has...